I 
118TH CONGRESS 
1ST SESSION 
H. R. 767 
To preserve access to abortion medications. 
IN THE HOUSE OF REPRESENTATIVES 
FEBRUARY 2, 2023 
Ms. BUSH (for herself, Ms. OMAR, Mr. SOTO, Ms. JACKSON LEE, Ms. MCCOL-
LUM, Ms. NORTON, Mr. BEYER, and Mr. CARSON) introduced the fol-
lowing bill; which was referred to the Committee on Energy and Com-
merce 
A BILL 
To preserve access to abortion medications. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Protecting Access to 
Medication Abortion Act of 2023’’. 
SEC. 2. MODIFICATION OF REMS. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services (referred to in this section as the ‘‘Sec-
retary’’) shall ensure that the risk evaluation and mitiga-
tion strategy under section 505–1 of the Federal Food, 
VerDate Sep 11 2014 
00:05 Feb 24, 2023
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H767.IH
H767
kjohnson on DSK79L0C42PROD with BILLS
Drug, and Cosmetic Act (21 U.S.C. 355–1) that applies 
to mifepristone— 
(1) does not have an in-person dispensing re-
quirement for such drug; 
(2) allows for patient access to prescriptions for 
such drug via telehealth; and 
(3) allows all pharmacies that are certified to 
dispense such drug to, at minimum, dispense and 
mail such drug to patients. 
(b) MODIFICATIONS.—Nothing in subsection (a) shall 
be construed to prevent the Secretary from approving a 
modification to the risk evaluation and mitigation strategy 
for mifepristone based on sound scientific evidence and in 
accordance with section 505–1(h) of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 355–1(h)), except 
that any modifications to such risk evaluation and mitiga-
tion strategy made after January 3, 2023, shall be in ac-
cordance with the requirements under paragraphs (1), (2), 
and (3) of subsection (a), unless the Secretary, based on 
sound scientific evidence and in accordance with section 
505–1 of such Act (21 U.S.C. 355–1), determines that 
a risk evaluation and mitigation strategy for mifepristone 
is no longer necessary. 
(c) CLARIFICATION.—Nothing in subsection (a) shall 
be construed to limit the authority of the Secretary to im-
VerDate Sep 11 2014 
00:05 Feb 24, 2023
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H767.IH
H767
kjohnson on DSK79L0C42PROD with BILLS
pose the requirements described in paragraphs (1), (2), 
and (3) of such subsection to a risk evaluation and mitiga-
tion strategy under section 505–1 of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 355–1) for any drug 
other than mifepristone. 
(d) 
DEFINITION.—In 
this 
section, 
the 
term 
‘‘mifepristone’’ means mifepristone that is— 
(1) approved under subsection (c) or (j) of sec-
tion 505 of the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 355); 
(2) indicated for medical abortion; and 
(3) subject to a risk evaluation and mitigation 
strategy under section 505–1 of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 355–1). 
Æ 
VerDate Sep 11 2014 
00:05 Feb 24, 2023
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H767.IH
H767
kjohnson on DSK79L0C42PROD with BILLS